Management Team


Pete DeComo Peter M. DeComo, the Chairman and Chief Executive Officer recently founded and shepherded Renal Solutions to a $200 million acquisition by Fresenius Medical Care in late 2007. In addition, he is a registered respiratory therapist, and has an extensive background in extracorporeal therapies.
Nick Kuhn Nicholas J. Kuhn, President and Chief Business Officer has extensive experience in the respiratory medical device industry, having held senior sales, marketing and operational positions at Baxter, Resmed, and Nellcor Puritan Bennett.
Joe Argyros Joseph Argyros, Senior Vice President – Operations has extensive experience in leading medical device product development, manufacturing and service operations. He has held senior positions in these capacities at Neuro Kinetics and Nomos.
Matt Burlando Matthew J. Burlando, Vice President – Finance and Administration has extensive experience in finance, accounting, and audit in the respiratory medical device industry. He most recently held a senior position with Respironics. Mr. Burlando obtained his MBA from the University of Pittsburgh and is a licensed CPA.
Frank Falcione Frank J. Falcione, Senior Vice President – Regulatory Affairs and Quality Assurance has extensive experience in FDA submissions and ISO quality system implementation. He has held senior positions in these capacities at CHS Business Associates, Emerson and Chiron Diagnostics.
Scott Morley Scott W. Morley, Vice President – Marketing has an extensive background in biomedical engineering and clinical affairs, having held senior positions in both of these roles at ALung. He has been with the Company since 2003.
Jim Sweeney James Sweeney, Senior Vice President – Corporate Development has extensive experience in business development. He has served in numerous senior level positions at Baxter International over a seventeen year period, including VP of Strategy Development for the 1.7B Renal Division.
Laura Lund Laura W. Lund, PhD, Director – Scientific Affairs has extensive experience in the research, design, and validation of blood gas exchange technology. Prior to ALung, Dr. Lund was an assistant professor in the Department of Bioengineering at the University of Pittsburgh’s Swanson School of Engineering.
Alethea Wieland Alethea Wieland, Director – Clinical Affairs has over 17 years of leadership experience in US and international device and drug clinical research, and 5 years of program management experience in continuing medical education.
  Regis M. George, Director – Product Development has held numerous development engineering roles in the high reliability / mission critical / life critical domains for both government and private industry and has over thirty years’ experience in product development and technical leadership roles.
 Rachel Allen Rachel Allen, General Counsel of ALung Technologies, Inc. has over 20 years of experience acting as the principal outside lawyer on numerous completed M&A, venture capital, and private equity transactions in a variety of industries, including health care, medical device, and energy.




Nausherwan Burki, M.D., Ph.D., Medical Director and Chairman of the Medical Advisory Board, is Professor, Department of Medicine, Division of Pulmonary & Critical Care Medicine at the University of Connecticut Health Center, Farmington, Connecticut. As a physician-scientist with expertise in both the physiology and treatment of lung disease, Dr. Burki directs the Company’s clinical research programs.

William Federspiel, Ph.D., Chairman of the Scientific Advisory Board and co-founder, is the Director of the Medical Devices Laboratory, McGowan Institute for Regenerative Medicine, University of Pittsburgh where he is a William Kepler Whiteford Professor of Bioengineering, Chemical Engineering, and Critical Care Medicine.

Board of Directors


Peter M. DeComo, Chairman and Chief Executive Officer.

Nicholas J. Kuhn, President and Chief Business Officer.

Nicholas Cullen, a board member, is a former Executive Vice President of Bayer Corporation, and former President of its Plastics Division. His primary responsibilies were in marketing, sales, and business management at Bayer with focus on polyurethanes, coatings, and plastics.

Gary G. Glausser, a board member, is the Chief Investment Officer of Innovation Works (IW). Gary oversees IW’s investment fund(s), chairs its Investment Committee and helps IW source, evaluate and invest in the region’s most promising startups. He is also General Partner at Birchmere Ventures a fully invested venture capital fund with $160 million under management. Mr. Glausser has over 30 years experience in financial management, investing, lending, and public accounting.

Gerald E. McGinnis, a board member, is the founder and former Chairman of Respironics, a company he sold to Philips Medical for $5.1 billion in 2008. He has career-long experience in pulmonary products, both in home and hospital care.

John McIlwraith, a board member, is a Managing Director at Allos Ventures, an early-stage venture capital firm.

William B. Ross, a board member, is former Chief Executive Officer of Sensormedics, and Chief Operating Officer of Viasys Healthcare. He has 33 years of experience in the critical care industry.

Joseph J. Stevens, a board member, has extensive experience in chemical manufacturing and business development. He was instrumental in the establishment of Renal Solutions and served as a member of its Board. He is a partner in NextChem, LLC, a chemical technology developer, and Senior Business Development Manager for Harcros Chemicals.